SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-112132"
 

Search: onr:"swepub:oai:DiVA.org:umu-112132" > Liver transplantati...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Liver transplantation for hereditary transthyretin amyloidosis : after 20 years still the best therapeutic alternative?

Ericzon, Bo-Göran (author)
Karolinska Institutet
Wilczek, Henryk E. (author)
Larsson, Marie (author)
show more...
Wijayatunga, Priyantha (author)
Umeå universitet,Statistik
Stangou, Arie (author)
Pena, João Rodrigues (author)
Furtado, Emanuel (author)
Barroso, Eduardo (author)
Daniel, Jorge (author)
Samuel, Didier (author)
Adam, Rene (author)
Karam, Vincent (author)
Poterucha, John (author)
Lewis, David (author)
Ferraz-Neto, Ben-Hur (author)
Cruz, Márcia Waddington (author)
Munar-Ques, Miguel (author)
Fabregat, Juan (author)
Ikeda, Shu-Ichi (author)
Ando, Yukio (author)
Heaton, Nigel (author)
Otto, Gerd (author)
Suhr, Ole (author)
Umeå universitet,Medicin
show less...
 (creator_code:org_t)
2015
2015
English.
In: Transplantation. - 0041-1337 .- 1534-6080. ; 99:9, s. 1847-1854
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BACKGROUND: Until recently, liver transplantation (Ltx) was the only available treatment for hereditary transthyretin (TTR) amyloidosis; today, however, several pharmacotherapies are tested. Herein, we present survival data from the largest available database on transplanted hereditary TTR patients to serve as a base for comparison.METHODS: Liver transplantation was evaluated in a 20-year retrospective analysis of the Familial Amyloidosis Polyneuropathy World Transplant Registry.RESULTS: From April 1990 until December 2010, data were accumulated from 77 liver transplant centers. The Registry contains 1940 patients, and 1379 are alive. Eighty-eight Ltx were performed in combination with a heart and/or kidney transplantation. Overall, 20-year survival after Ltx was 55.3%. Multivariate analysis revealed modified body mass index, early onset of disease (<50 years of age), disease duration before Ltx, and TTR Val30Met versus non-TTR Val30Met mutations as independent significant survival factors. Early-onset patients had an expected mortality rate of 38% that of the late-onset group (P < 0.001). Furthermore, Val30Met patients had an expected mortality rate of 61% that of non-TTR Val30Met patients (P < 0.001). With each year of duration of disease before Ltx, expected mortality increased by 11% (P < 0.001). With each 100-unit increase in modified body mass index at Ltx, the expected mortality decreased to 89% of the expected mortality (P < 0.001). Cardiovascular death was markedly more common than that observed in patients undergoing Ltx for end-stage liver disease.CONCLUSIONS: Long-term survival after Ltx, especially for early-onset TTR Val30Met patients, is excellent. The risk of delaying Ltx by testing alternative treatments, especially in early-onset TTR Val30Met patients, requires consideration.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view